Advertisement

Treatment of Drooling in Parkinson’s Disease

  • Stephen GrillEmail author
Chapter
  • 499 Downloads
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

Persons with Parkinson’s disease are frequently not able to control their saliva and then experience drooling. This is irritating and embarrassing to patients but also may lead to significant medical consequences increasing the risk of aspiration pneumonia. Those with minimal drooling do not need specific treatment. For patients with more severe drooling, a stepped approach is taken. This includes the use of anticholinergic agents including sublingual atropine drops and, if that is not sufficient, botulinum toxin injections targeting the parotid and submandibular glands.

Keywords

Drooling Sialorrhea Atropine drops Botulinum toxin Salivary glands 

Supplementary material

Video 16.1

This demonstrates the technique for injecting botulinum toxin for drooling. The parotid injection is given half-way between the angle of the mandible and the external auditory canal (in this case 2500 units of rimabotulinum b were injected based on the patient’s prior response). The injection into the submandibular gland (1500 units) is given half-way between the front of the jaw and the angle of the jaw, about 1 cm medially. (WMV 85057 kb)

Suggested Reading

  1. Barbe AG, Bock N, Derman SHM, Relsch M, Timmermann L, Noack MJ. Self-assessment of oral health, dental health care and oral health-related quality of life among Parkinson’s disease patients. Gerodontology. 2016. (Note: this is still listed as “ahead of print” on-line and I cannot find the full reference as of now).Google Scholar
  2. Bateson MC, Gibberd FB, Wilson RSE. Salivary symptoms in Parkinson’s disease. Arch Neurol. 1973;29:274–5.CrossRefGoogle Scholar
  3. Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007;22:2306–13.CrossRefGoogle Scholar
  4. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompilli M, Masciana R, Sicilliani L, Sabatelli M, Bentivoglop AR. Botulinum toxin a versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord. 2011;26(2):313–9.CrossRefGoogle Scholar
  5. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17(6):1318–20.CrossRefGoogle Scholar
  6. Karakoc M, Yon M, Cakmakli G, Ulusoy E, Gulunay A, Oztekin N, Ak F. Pathophysiology underlying drooling in Parkinson’s disease: oropharyngeal bradykinesia. Neurol Sci. 2016;37:1987.CrossRefGoogle Scholar
  7. Leibner J, Ramjit A, Sedig L, Dai Y, Wu SS, Jacobson C, Okun M, Rodriguez RL, Malaty IA, Fernandez HH. The impact of and the factors associated with drooling in Parkinson’s disease. Parknsonism Rel Disord. 2010;16:475–7.CrossRefGoogle Scholar
  8. Rodriques BZ, Nobrega AC, Sampaio M, Argolo N, Melo A. Silent saliva aspiration in Parkinson’s disease. Mov Disord. 2011;26(1):138–41.CrossRefGoogle Scholar
  9. Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinson’s disease: a review. Parkinsonism Rel Disord. 2014;20(11):1109–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Parkinson’s and Movement Disorders Center of MarylandElkridgeUSA

Personalised recommendations